Antidepressants: SSRIs, SNRIs, TCAs, MAOIs, Clinical Use and Tapering

Educational pharmacology review updated 10 November 2026. This information does not replace a patient-specific clinical evaluation or current local prescribing guidance.

Introduction

Antidepressants are used for major depressive disorder and selected anxiety, obsessive-compulsive, pain and other conditions. Choice should incorporate symptom severity, patient preference, prior response, comorbidity, interacting medicines, pregnancy considerations and access to evidence-based psychological treatments [1,2].

Correct pharmacologic classification

  • SSRIs: sertraline, fluoxetine, escitalopram and others inhibit the serotonin transporter (SERT).
  • SNRIs: venlafaxine, desvenlafaxine and duloxetine inhibit SERT and norepinephrine transporters.
  • Tricyclic antidepressants (TCAs): amitriptyline, nortriptyline and imipramine inhibit monoamine reuptake but also have antimuscarinic, antihistamine and alpha-1 blocking effects.
  • MAO inhibitors: phenelzine and tranylcypromine inhibit monoamine breakdown; specialist use requires strict interaction precautions.
  • Other: bupropion mainly inhibits norepinephrine/dopamine transporters; mirtazapine blocks presynaptic alpha-2 and selected serotonin receptors; vortioxetine has serotonin transporter and receptor actions; trazodone has mixed serotonergic actions [1].

Treatment selection and response

NICE NG222 advises discussing the full range of management options and considering individual preferences. SSRIs are commonly preferred when medication is chosen because of tolerability and lower overdose toxicity than TCAs. Assess suicidal thoughts, agitation, bipolar history and adverse effects early after starting therapy. Benefits often emerge over several weeks; an inadequate response warrants reviewing diagnosis, adherence, dose and psychotherapy rather than reflexively adding interacting drugs [2].

Adverse effects

SSRIs/SNRIs may cause nausea, sexual dysfunction, sleep disturbance, sweating and sometimes hyponatremia or bleeding (particularly with NSAIDs/anticoagulants). SNRIs may elevate blood pressure. TCAs can cause orthostasis, urinary retention, constipation, sedation and dangerous sodium-channel-mediated cardiotoxicity in overdose. Bupropion may provoke seizures in susceptible patients; mirtazapine may cause appetite increase, weight gain and sedation. Antidepressants may precipitate mania in bipolar disorder [1,2].

Interactions and serotonin toxicity

Combining serotonergic drugs with MAO inhibitors, linezolid or some analgesics can produce serotonin toxicity with clonus, hyperreflexia, fever or autonomic instability. Fluoxetine has a long elimination half-life and inhibits CYP2D6; paroxetine also inhibits CYP2D6. Citalopram and escitalopram can prolong QT at higher exposure. MAO inhibitors require specific food and medicine restrictions and washout periods [1].

Safe tapering and withdrawal

NICE advises reducing antidepressants gradually in stages when stopping. Abrupt cessation or missed doses can cause dizziness, electric-shock sensations, insomnia, nausea and anxiety; withdrawal may be especially troublesome with paroxetine and venlafaxine, while fluoxetine’s long half-life often reduces immediate risk. Patients with severe symptoms may need a slower, individually supported taper. Withdrawal symptoms are not necessarily recurrence of depression, but monitoring for relapse and suicidality remains important [2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. National Institute for Health and Care Excellence. Depression in adults: treatment and management. NICE guideline NG222. 2022. Available from: https://www.nice.org.uk/guidance/ng222/chapter/recommendations
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *